Victor Freire Ferreira de Aguilar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Victor Freire Ferreira de Aguilar has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Laura Grossi de Oliveira
Programa de Pós‐Graduação em Ciências da Saúde: Infectologia e Medicina Tropical Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil
1 shared publication - Diego Ribeiro
Department of Veterinary Clinic Faculty of Veterinary Medicine and Zootechny São Paulo State University (UNESP) Botucatu São Paulo Brazil
1 shared publication - Josiane Aparecida Martiniano de Pádua
Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais – UFMG, Belo Horizonte, Brasil
1 shared publication - Kelly Moura Keller
Universidade Federal de Minas Gerais, Brasil
1 shared publication - Lilian Lacerda Bueno
Post-Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte 30130-100, Brazil
1 shared publication - Ricardo Toshio Fujiwara
Laboratory of Immunobiology and Parasite Control, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
1 shared publication
Latest Publications
- Open Access
Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions
Visceral leishmaniasis is a zoonosis commonly caused in Brazil by the parasite Leishmania infantum. This protozoan parasite can infect several species of mammals, with dogs being the main reservoir in urban areas. Several methods are used to prevent the disease, including collars impregnated with 4% deltamethrin to prevent contact between the sandfly and the animal, and vaccines. Vaccines aim to stimulate an immune response that can effectively fight the parasite, with the Th1 immune response being the most desired. There are several research groups around the world dedicated to testing new immunogens against Leishmania spp. and there are currently two commercially available vaccines used to prevent the disease, Neoleish® and Leti-Fend®. Leish-Tec®, a vaccine previously licensed for use in dogs in Brazil, was suspended in May 2023 due to non-compliance in some batches. This also happened with CaniLeish®, which was discontinued by the European Commission in October 2023. These vaccines have different characteristics that influence their use as a public health measure, and therefore the objective of this review is to describe these immunogens, their characteristics, and their use as a collective prevention measure for canine visceral leishmaniasis.
Open AccessOverview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions
Visceral leishmaniasis is a zoonosis commonly caused in Brazil by the parasite Leishmania infantum. This protozoan parasite can infect several species of mammals, with dogs being the main reservoir in urban areas. Several methods are used to prevent the disease, including collars impregnated with 4% deltamethrin to prevent contact between the sandfly and the animal, and vaccines. Vaccines aim to stimulate an immune response that can effectively fight the parasite, with the Th1 immune response being the most desired. There are several research groups around the world dedicated to testing new immunogens against Leishmania spp. and there are currently two commercially available vaccines used to prevent the disease, Neoleish® and Leti-Fend®. Leish-Tec®, a vaccine previously licensed for use in dogs in Brazil, was suspended in May 2023 due to non-compliance in some batches. This also happened with CaniLeish®, which was discontinued by the European Commission in October 2023. These vaccines have different characteristics that influence their use as a public health measure, and therefore the objective of this review is to describe these immunogens, their characteristics, and their use as a collective prevention measure for canine visceral leishmaniasis.